DelveInsight’s, “Trigeminal Neuralgia Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Trigeminal Neuralgia pipeline landscape. It covers the Trigeminal Neuralgia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Trigeminal Neuralgia Pipeline Report

• DelveInsight’s Trigeminal Neuralgia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Trigeminal Neuralgia treatment.
• The leading companies working in the Trigeminal Neuralgia Market include Biogen, Biohaven Pharmaceuticals, Noema Pharma AG, Pfizer, and others.
• Promising Trigeminal Neuralgia Pipeline Therapies in the various stages of development include Carbon Dioxide Drug Delivery System (CDDS), Basimglurant, CNV1014802, BIIB074, Galcanezumab, COA566, and others.
• On March 2023, Duke University announced a study of Phase 4 Clinical Trials for Galcanezumab. The investigators will treat patients (targeting enrollment of n=20) who suffer from trigeminal or glossopharyngeal nerve pain in the context of painful small fiber neuropathy. The primary pain-related objective is reduction of pain and reduced use of rescue and other anti-pain medications. Another goal is to monitor and confirm the safety profile established in the migraine population, during previous Phase 3 trials.
• On August 2023, Noema Pharma AG announced a study of Phase 2 & 3 Clinical Trials for Basimglurant. This study is designed to evaluate the efficacy and safety of 1.5mg – 3.5mg basimglurant in adults with Trigeminal Neuralgia.

 

Request a sample and discover the recent advances in Trigeminal Neuralgia Treatment Drugs @ Trigeminal Neuralgia Pipeline Report

 

The Trigeminal Neuralgia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Trigeminal Neuralgia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Trigeminal Neuralgia clinical trial landscape.

 

Trigeminal Neuralgia Overview

Trigeminal Neuralgia is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock–like or stabbing pain in a region of the face. The pain of trigeminal neuralgia most frequently affects the distribution of the second (maxillary) or third (mandibular) division of the trigeminal nerve, with the right side of the face affected more often than the left side.

 

Find out more about Trigeminal Neuralgia Treatment Drugs @ Drugs for Trigeminal Neuralgia Treatment

 

Trigeminal Neuralgia Emerging Drugs Profile

• Vixotrigine: Biogen
• Rimegepant: Biohaven Pharmaceuticals

 

Trigeminal Neuralgia Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Trigeminal Neuralgia. The Trigeminal Neuralgia companies which have their Trigeminal Neuralgia drug candidates in the most advanced stage, i.e. phase III include, Biogen.

 

Learn more about the emerging Trigeminal Neuralgia Pipeline Therapies @ Trigeminal Neuralgia Clinical Trials Assessment

 

Scope of the Trigeminal Neuralgia Pipeline Report

• Coverage- Global
• Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Trigeminal Neuralgia Companies- Biogen, Biohaven Pharmaceuticals, Noema Pharma AG, Pfizer, and others.
• Trigeminal Neuralgia Pipeline Therapies- Carbon Dioxide Drug Delivery System (CDDS), Basimglurant, CNV1014802, BIIB074, Galcanezumab, COA566, and others.

 

Dive deep into rich insights for new drugs for Trigeminal Neuralgia Treatment, Visit @ Trigeminal Neuralgia Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Trigeminal Neuralgia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Trigeminal Neuralgia – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Trigeminal Neuralgia Collaboration Deals
9. Late Stage Products (Phase III)
10. Vixotrigine: Biogen
11. Mid Stage Products (Phase II)
12. Rimegepant: Biohaven Pharmaceuticals
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. GTX201: Grace Therapeutics
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. TNX-1900: Tonix Pharmaceuticals
19. Drug profiles in the detailed report…..
20. Inactive Products
21. Trigeminal Neuralgia Key Companies
22. Trigeminal Neuralgia Key Products
23. Trigeminal Neuralgia- Unmet Needs
24. Trigeminal Neuralgia- Market Drivers and Barriers
25. Trigeminal Neuralgia- Future Perspectives and Conclusion
26. Trigeminal Neuralgia Analyst Views
27. Trigeminal Neuralgia Key Companies
28. Appendix

 

For further information on the Trigeminal Neuralgia Pipeline therapeutics, reach out to Trigeminal Neuralgia Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting